Effects of tachykinin NK1 receptor antagonists on the viscerosensory response caused by colorectal distention in rabbits.

Irritable bowel syndrome (IBS) is a common disorder mainly characterized by altered bowel habits and visceral pain. In this study, we investigated the role of tachykinin NK1 receptors in the visceral pain response (abdominal muscle contraction) caused by colorectal distention in rabbits previously subjected to colonic irritation, using the selective tachykinin NK1 receptor antagonists TAK-637 [(aR,9R)-7-[3,5-Bis(trifluoromethyl)benzyl]-8,9,10,11-tetrahydro-9-methyl-5-(4-methylphenyl)-7H-[1,4] diazocino[2,1-g][1,7]naphthyridine-6,13-dione] and (+/-)-CP-99,994 (+/-)-(2S,3S)-3-(2-methoxybenzylamino)-2-phenylpiperidine. Intracolorectal administration of 0.8% acetic acid solution enhanced the nociceptive response to colorectal distention, producing a significant increase in the number of abdominal muscle contractions. Under these conditions, intraduodenal TAK-637 (0.1-3 mg/kg) dose dependently decreased the number of distention-induced abdominal contractions, and a significant inhibitory effect was observed with doses of 0.3 to 3 mg/kg. Another tachykinin NK1 antagonist, (+/-)-CP-99,994, also reduced the number of abdominal contractions. In contrast, the enantiomer of TAK-637 (which has very weak tachykinin NK1 receptor antagonistic activity), trimebutine maleate, ondansetron, and atropine sulfate did not inhibit the abdominal response. The main metabolite of TAK-637, which has more potent tachykinin NK1 receptor antagonistic activity but permeates the central nervous system less well than TAK-637, produced less inhibition of the viscerosensory response. When given intrathecally, TAK-637 and (+/-)-CP-99,994 markedly reduced the number of abdominal contractions. These results suggest that tachykinin NK1 receptors play an important role in mediating visceral pain and that TAK-637 inhibits the viscerosensory response to colorectal distention by antagonizing tachykinin NK1 receptors, mainly in the spinal cord. They also suggest that TAK-637 may be useful in treating functional bowel disorders such as IBS.

[1]  H. Natsugari,et al.  Effects of TAK-637, a novel neurokinin-1 receptor antagonist, on colonic function in vivo. , 2001, The Journal of pharmacology and experimental therapeutics.

[2]  P. Pasricha,et al.  A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development. , 2000, Gastroenterology.

[3]  B. Kirkham,et al.  Effects of the peripherally selective κ -opioid asimadoline, on substance P and CGRP mRNA expression in chronic arthritis of the rat , 2000, Neuropeptides.

[4]  C. Roza,et al.  Deficits in visceral pain and hyperalgesia of mice with a disruption of the tachykinin NK1 receptor gene , 2000, Neuroscience.

[5]  D. Drossman.  Do psychosocial factors define symptom severity and patient status in irritable bowel syndrome? , 1999, The American journal of medicine.

[6]  A. Fujishima,et al.  Axially chiral 1,7-naphthyridine-6-carboxamide derivatives as orally active tachykinin NK(1) receptor antagonists: synthesis, antagonistic activity, and effects on bladder functions. , 1999, Journal of medicinal chemistry.

[7]  J. Laird,et al.  Differential effects of N-Methyl-d-aspartate receptor blockade on nociceptive somatic and visceral reflexes , 1999, Pain.

[8]  R G Hill,et al.  Distinct mechanism for antidepressant activity by blockade of central substance P receptors. , 1998, Science.

[9]  P. Mclean,et al.  Effects of tachykinin receptor antagonists on the rat jejunal distension pain response. , 1998, European journal of pharmacology.

[10]  C. Epstein,et al.  Primary afferent tachykinins are required to experience moderate to intense pain , 1998, Nature.

[11]  M. Palkovits,et al.  Hypoalgesia in mice with a targeted deletion of the tachykinin 1 gene. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[12]  C. Maggi,et al.  The tachykinin NK1 receptor. Part II: Distribution and pathophysiological roles , 1998, Neuropeptides.

[13]  Y. Taché,et al.  Proximal colon distention increases Fos expression in the lumbosacral spinal cord and activates sacral parasympathetic NADPHd‐positive neurons in rats , 1998, The Journal of comparative neurology.

[14]  V. Théodorou,et al.  Stress‐induced visceral hypersensitivity to rectal distension in rats: role of CRF and mast cells , 1997, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[15]  P. Mclean,et al.  Effects of nematode infection on sensitivity to intestinal distension: role of tachykinin NK2 receptors. , 1997, European journal of pharmacology.

[16]  E A Mayer,et al.  Evidence for two distinct perceptual alterations in irritable bowel syndrome , 1997, Gut.

[17]  J. Malagelada,et al.  Attention and distraction: effects on gut perception. , 1997, Gastroenterology.

[18]  R. Quirion,et al.  Calcitonin gene-related peptide in viscerosensitive response to colorectal distension in rats. , 1997, The American journal of physiology.

[19]  S. Dahl,et al.  Fedotozine blocks hypersensitive visceral pain in conscious rats: action at peripheral kappa-opioid receptors. , 1997, European journal of pharmacology.

[20]  U. Holzer‐Petsche,et al.  Tachykinins in the gut. Part I. Expression, release and motor function. , 1997, Pharmacology & therapeutics.

[21]  S. Boyce,et al.  Enantioselective inhibition of the formalin paw late phase by the NK1 receptor antagonist L-733,060 in gerbils , 1996, PAIN.

[22]  P. Whorwell,et al.  Selective 5‐hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia? , 1996, Alimentary pharmacology & therapeutics.

[23]  N. Read,et al.  Psychometric scores and persistence of irritable bowel after infectious diarrhoea , 1996, The Lancet.

[24]  E A Mayer,et al.  Altered rectal perception is a biological marker of patients with irritable bowel syndrome. , 1995, Gastroenterology.

[25]  J. Longhurst,et al.  Role of spinal NK1 receptors in cardiovascular responses to chemical stimulation of the gallbladder. , 1995, The American journal of physiology.

[26]  T. Poynard,et al.  Meta‐analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome , 2001, Alimentary pharmacology & therapeutics.

[27]  E. Drack,et al.  Substance P activates rat colonic motility via excitatory and inhibitory neural pathways and direct action on muscles. , 1994, The Journal of pharmacology and experimental therapeutics.

[28]  E A Mayer,et al.  Basic and clinical aspects of visceral hyperalgesia. , 1994, Gastroenterology.

[29]  R. Spike,et al.  The localization of classical transmitters and neuropeptides within neurons in laminae I–III of the mammalian spinal dorsal horn , 1993, Progress in Neurobiology.

[30]  A. Dickenson,et al.  The effect of intrathecal administration of RP67580, a potent neurokinin 1 antagonist on nociceptive transmission in the rat spinal cord , 1993, Neuroscience Letters.

[31]  K. Yoshioka,et al.  Neurotransmitter functions of mammalian tachykinins. , 1993, Physiological reviews.

[32]  P. Thadeio,et al.  Discovery of a potent substance P antagonist: recognition of the key molecular determinant. , 1992, Journal of medicinal chemistry.

[33]  M. Satoh,et al.  Effects of intrathecal antibodies to substance P, calcitonin gene-related peptide and galanin on repeated cold stress-induced hyperalgesia: comparison with carrageenan-induced hyperalgesia , 1992, Pain.

[34]  R. Hagan,et al.  Investigation into species variants in tachykinin NK1 receptors by use of the non‐peptide antagonist, CP‐96,345 , 1991, British journal of pharmacology.

[35]  A. Nakamura,et al.  Involvement of substance P in hyperalgesia induced by intrathecal galanin , 1991, Neuroscience Research.

[36]  T. Ness,et al.  Visceral pain: a review of experimental studies , 1990, Pain.

[37]  T. Ness,et al.  Colorectal distension as a noxious visceral stimulus: physiologic and pharmacologic characterization of pseudaffective reflexes in the rat , 1988, Brain Research.

[38]  F. Lembeck,et al.  DECREASE OF SUBSTANCE P IN PRIMARY AFFERENT NEURONES AND IMPAIRMENT OF NEUROGENIC PLASMA EXTRAVASATION BY CAPSAICIN , 1980, British journal of pharmacology.

[39]  T. Yaksh,et al.  Chronic catheterization of the spinal subarachnoid space , 1976, Physiology & Behavior.